170 related articles for article (PubMed ID: 18786288)
21. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
Richard SD; Sukumvanich P; Lesnock JL; McBee WC; Beriwal S; Edwards RP; Zorn KK; Krivak TC
Int J Gynecol Cancer; 2010 Aug; 20(6):932-5. PubMed ID: 20683398
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
24. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer.
Colaković S; Lukiç V; Mitroviç L; Jeliç S; Susnjar S; Marinkoviç J
Int J Biol Markers; 2000; 15(2):147-52. PubMed ID: 10883888
[TBL] [Abstract][Full Text] [Related]
27. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Bogani G; Matteucci L; Tamberi S; Ditto A; Sabatucci I; Murgia F; Arcangeli V; Maltese G; Comerci G; Stefanetti M; Sonetto C; Calareso G; Marchiano A; Chiappa V; Lorusso D; Raspagliesi F
Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():93-99. PubMed ID: 31029972
[TBL] [Abstract][Full Text] [Related]
28. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
Ann Surg Oncol; 2007 Sep; 14(9):2649-53. PubMed ID: 17562112
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
[TBL] [Abstract][Full Text] [Related]
30. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer.
Liao YC; Ou YC; Wu CH; Fu HC; Tsai CC; Lin H
Cancer Biomark; 2021; 32(4):559-567. PubMed ID: 34397404
[TBL] [Abstract][Full Text] [Related]
31. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.
Rosen B; Laframboise S; Ferguson S; Dodge J; Bernardini M; Murphy J; Segev Y; Sun P; Narod SA
Gynecol Oncol; 2014 Sep; 134(3):462-7. PubMed ID: 25026637
[TBL] [Abstract][Full Text] [Related]
32. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
Chudecka-Głaz A; Cymbaluk-Płoska A; Wężowska M; Menkiszak J
PLoS One; 2018; 13(3):e0194270. PubMed ID: 29584739
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer.
Potenza E; Parpinel G; Laudani ME; Macchi C; Fuso L; Zola P
Int J Biol Markers; 2020 Dec; 35(4):20-27. PubMed ID: 33126819
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
35. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
[TBL] [Abstract][Full Text] [Related]
36. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jul; 106(1):160-3. PubMed ID: 17490737
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
Riedinger JM
Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
[TBL] [Abstract][Full Text] [Related]
38. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
39. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
40. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Han LY; Karavasilis V; Hagen Tv; Nicum S; Thomas K; Harrison M; Papadopoulos P; Blake P; Barton DP; Gore M; Kaye SB
Eur J Cancer; 2010 May; 46(8):1359-64. PubMed ID: 20303743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
